Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Change in Accured Expenses (2016 - 2025)

Cytosorbents (CTSO) has disclosed Change in Accured Expenses for 14 consecutive years, with $193000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Accured Expenses rose 117.02% year-over-year to $193000.0, compared with a TTM value of $1.2 million through Sep 2025, up 145.71%, and an annual FY2024 reading of -$1.8 million, down 212.46% over the prior year.
  • Change in Accured Expenses was $193000.0 for Q3 2025 at Cytosorbents, up from $7282.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $2.1 million in Q4 2021 and bottomed at -$1.3 million in Q1 2024.
  • Average Change in Accured Expenses over 5 years is -$62598.8, with a median of -$206441.0 recorded in 2022.
  • The sharpest move saw Change in Accured Expenses crashed 490.9% in 2022, then soared 371.1% in 2023.
  • Year by year, Change in Accured Expenses stood at $2.1 million in 2021, then crashed by 109.71% to -$206441.0 in 2022, then soared by 371.1% to $559666.0 in 2023, then soared by 142.72% to $1.4 million in 2024, then plummeted by 85.79% to $193000.0 in 2025.
  • Business Quant data shows Change in Accured Expenses for CTSO at $193000.0 in Q3 2025, $7282.0 in Q2 2025, and -$367282.0 in Q1 2025.